Evidence map›Paper›PMID 20859676›Full record

ArticleBreast cancer research and treatment2011

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

Sean D McAllister, Ryuichi Murase, Rigel T Christian, Darryl Lau, Anne J Zielinski, Juanita Allison, Carolina Almanza, Arash Pakdel, Jasmine Lee, Chandani Limbad and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 223 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Sean D McAllisterCalifornia Pacific Medical Center, Research Institute, San Francisco, CA 94107, USA. mcallis@cpmcri.org
Ryuichi Murase
Rigel T Christian
Darryl Lau
Anne J Zielinski
Juanita Allison
Carolina Almanza
Arash Pakdel
Jasmine Lee
Chandani Limbad
Yong Liu
Robert J Debs
Dan H Moore
Pierre-Yves Desprez
California Pacific Medical Center · US

Funding

Cannabinoids Control Breast Cancer Progression Through Id-1R01CA135281 · NCI · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI MCALLISTER, SEAN D · 2009 to 2012
$1.4M
MOLECULAR MECHANISMS OF CANNABINOID RECEPTOR REGULATIONR01DA009978 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABOOD, MARY E · 1996 to 2006
$1.1M
ID-1 EXPRESSION IN BREAST EPITHELIAL CELLSR01CA082548 · NCI · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI DESPREZ, PIERRE-YVES · 1999 to 2002
$644k
Control of Breast Cancer by the Endocannabinoid SystemK01CA111723 · NCI · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI MCALLISTER, SEAN D · 2006 to 2009
$638k
Molecular Mechanisms of Cannabinoid Antitumor ActivityR21CA102412 · NCI · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI MCALLISTER, SEAN D · 2005 to 2006
$363k
NCI NIH HHS CA082548NCI NIH HHS CA102412NCI NIH HHS CA111723NCI NIH HHS CA135281NCI NIH HHS K01 CA111723NCI NIH HHS R01 CA082548NCI NIH HHS R01 CA135281NCI NIH HHS R21 CA102412NIDA NIH HHS DA09978NIDA NIH HHS R01 DA009978
6 · The paper itself

Abstract

Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Therefore, effective, targeted, and non-toxic therapies are urgently required. Id-1, an inhibitor of basic helix-loop-helix transcription factors, has recently been shown to be a key regulator of the metastatic potential of breast and additional cancers. We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, down-regulated Id-1 gene expression in aggressive human breast cancer cells in culture. Using cell proliferation and invasion assays, cell flow cytometry to examine cell cycle and the formation of reactive oxygen species, and Western analysis, we determined pathways leading to the down-regulation of Id-1 expression by CBD and consequently to the inhibition of the proliferative and invasive phenotype of human breast cancer cells. Then, using the mouse 4T1 mammary tumor cell line and the ranksum test, two different syngeneic models of tumor metastasis to the lungs were chosen to determine whether treatment with CBD would reduce metastasis in vivo. We show that CBD inhibits human breast cancer cell proliferation and invasion through differential modulation of the extracellular signal-regulated kinase (ERK) and reactive oxygen species (ROS) pathways, and that both pathways lead to down-regulation of Id-1 expression. Moreover, we demonstrate that CBD up-regulates the pro-differentiation factor, Id-2. Using immune competent mice, we then show that treatment with CBD significantly reduces primary tumor mass as well as the size and number of lung metastatic foci in two models of metastasis. Our data demonstrate the efficacy of CBD in pre-clinical models of breast cancer. The results have the potential to lead to the development of novel non-toxic compounds for the treatment of breast cancer metastasis, and the information gained from these experiments broaden our knowledge of both Id-1 and cannabinoid biology as it pertains to cancer progression.

Indexed as

alpha-TocopherolAnimalsAntineoplastic AgentsAntioxidantsBreast NeoplasmsCannabidiolCell Line, TumorCell ProliferationDisease Models, AnimalExtracellular Signal-Regulated MAP KinasesFemaleHumansInhibitor of Differentiation Protein 1MiceMice, Inbred BALB CNeoplasm Invasivenessalpha-TocopherolAntineoplastic AgentsAntioxidantsCannabidiolExtracellular Signal-Regulated MAP KinasesID1 protein, humanInhibitor of Differentiation Protein 1

Identifiers

PMID20859676
PMCPMC3410650
OpenAlexW2143825529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.